Elite Pharmaceuticals, Inc.
Doug Plassche has a diverse and extensive work experience in the pharmaceutical industry. Doug began their career at Schering Plough in 1996, where they held various roles including Director of Production Operations and Manager of Start-Up. Doug then joined Par Pharmaceutical in 2007 as Senior Director of Manufacturing. In 2009, they joined Actavis as the Managing Director of NJ SOD, where they were responsible for multiple plant operations and had a significant budget and workforce under their supervision. Since 2013, Doug has been serving as the Executive Vice President of Operations at Elite Pharmaceuticals, Inc.
Doug Plassche's education history includes several notable experiences. In 1981, they attended the University of Rochester, where they pursued studies in an undisclosed field, and completed their education in 1985. Following this, from 1985 to 1987, they enrolled in Navy Nuclear Engineering, specializing in Nuclear Engineering. In 2006, they received Six Sigma Black Belt certification from ASQ. Finally, in 2010 and 2011, Doug furthered their education by earning a Certificate in Business from Cranfield School of Management.
This person is not in any teams
Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals (“ECR”), a wholly owned subsidiary of Hi-Tech Pharmacal (“Hi-Tech”). Elite’s lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.